// App-Quantinova.ai

512 : Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA).

Researchers

Presenter

  • Nicholas C. Turner

Principal Investigators

  • Yuqiu Jiang

  • Ben O'Leary

  • Sarah Hrebien

  • Massimo Cristofanilli

  • Fabrice Andre

  • Sibylle Loibl

  • Patricia A. English

  • Ke Zhang

  • Sophia Randolph

  • Cynthia Huang Bartlett

  • Maria Koehler

  • Sherene Loi

Medical Centers

  • Royal Marsden Hospital and Institute of Cancer Research, London, United Kingdom

  • Pfizer Inc, San Diego, CA

  • Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Chicago, IL

  • Institut Gustave-Roussy, Villejuif, France

  • German Breast Group (GBG), Neu-Isenbug, Germany

  • Pfizer Inc, New York, NY

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Germany

  • United Kingdom

  • Australia

  • United States

  • France

Companies

  • Pfizer Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • Estrogen Receptor 1

  • Circulating DNA

Drug/Treatment

  • Fulvestrant

  • Palbociclib

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • NCT01942135

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved